DE69939820D1 - Internalisierende erbb2 antikörper - Google Patents
Internalisierende erbb2 antikörperInfo
- Publication number
- DE69939820D1 DE69939820D1 DE69939820T DE69939820T DE69939820D1 DE 69939820 D1 DE69939820 D1 DE 69939820D1 DE 69939820 T DE69939820 T DE 69939820T DE 69939820 T DE69939820 T DE 69939820T DE 69939820 D1 DE69939820 D1 DE 69939820D1
- Authority
- DE
- Germany
- Prior art keywords
- internalizing
- antibodies
- erbb2
- erbb2 antibodies
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10041—Use of virus, viral particle or viral elements as a vector
- C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8295398P | 1998-04-24 | 1998-04-24 | |
US09/250,056 US7244826B1 (en) | 1998-04-24 | 1999-02-12 | Internalizing ERB2 antibodies |
PCT/US1999/007395 WO1999055367A1 (en) | 1998-04-24 | 1999-04-23 | INTERNALIZING ErbB2 ANTIBODIES |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69939820D1 true DE69939820D1 (de) | 2008-12-11 |
Family
ID=26768027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69939820T Expired - Lifetime DE69939820D1 (de) | 1998-04-24 | 1999-04-23 | Internalisierende erbb2 antikörper |
Country Status (9)
Country | Link |
---|---|
US (6) | US7244826B1 (de) |
EP (1) | EP1071460B1 (de) |
JP (1) | JP2002524024A (de) |
AT (1) | ATE412432T1 (de) |
AU (1) | AU769304B2 (de) |
CA (1) | CA2326377C (de) |
DE (1) | DE69939820D1 (de) |
ES (1) | ES2316186T3 (de) |
WO (1) | WO1999055367A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
KR20020047098A (ko) * | 1999-07-29 | 2002-06-21 | 추후제출 | HER2/neu에 대한 인간 모노클로날 항체 |
ES2393535T3 (es) * | 2000-04-17 | 2012-12-26 | Dyax Corp. | Nuevos métodos para construir bibliotecas de paquetes genéticos que presentan de forma colectiva los miembros de una familia diversa de péptidos, polipéptidos o proteínas |
US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
SI1282443T1 (sl) | 2000-05-19 | 2010-01-29 | Genentech Inc | Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB |
AU2002249854B2 (en) | 2000-12-18 | 2007-09-20 | Dyax Corp. | Focused libraries of genetic packages |
ITRM20010408A1 (it) * | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
WO2003009870A1 (fr) * | 2001-07-25 | 2003-02-06 | Mitsubishi Pharma Corporation | Remedes traitant le cancer du sein |
AU2003256299A1 (en) | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US6987270B2 (en) | 2003-05-07 | 2006-01-17 | General Electric Company | Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes |
ATE422880T1 (de) | 2003-08-26 | 2009-03-15 | Smithkline Beecham Corp | Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen |
BRPI0416987A (pt) * | 2003-11-28 | 2007-08-21 | Mitra Medical Technology Ab | direcionamento de antìgenos de erb |
CN107811971B (zh) | 2004-05-03 | 2021-10-29 | 益普生生物制药公司 | 用于药物输送的脂质体 |
JP2008515929A (ja) | 2004-10-08 | 2008-05-15 | アルザ コーポレイション | 脂質連結部分を予備形成した脂質集合体にマイクロ波を使用して挿入する方法 |
CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
CN101146554B (zh) * | 2005-01-27 | 2012-10-10 | 加州大学评议会 | 中和肉毒杆菌神经毒素的治疗性单克隆抗体 |
GB0503546D0 (en) * | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
BRPI0606542A8 (pt) | 2005-02-23 | 2018-03-20 | Genentech Inc | métodos para aumentar o tempo de progressão de uma doença (ttp) |
SI2511301T1 (en) | 2006-08-04 | 2018-05-31 | MedImmune Limited, | Human antibodies to ERBB 2 |
CN101558156B (zh) * | 2006-12-12 | 2011-11-23 | 莫佛塞斯公司 | 内化 |
CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
CA2680741A1 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
US20090175784A1 (en) | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
CA3006428A1 (en) | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
DK3124497T3 (da) | 2007-09-14 | 2020-05-11 | Adimab Llc | Rationelt designede syntetiske antistofbiblioteker og anvendelser deraf |
US9873957B2 (en) | 2008-03-13 | 2018-01-23 | Dyax Corp. | Libraries of genetic packages comprising novel HC CDR3 designs |
JP5780951B2 (ja) | 2008-04-24 | 2015-09-16 | ダイアックス コーポレーション | 新規のhccdr1、cdr2、およびcdr3設計、ならびに新規のlccdr1、cdr2、およびcdr3設計を含む、遺伝子パッケージのライブラリ |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US9000131B2 (en) * | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
JP2012507299A (ja) | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Light標的分子およびその使用 |
US20120121596A1 (en) | 2009-03-20 | 2012-05-17 | Germaine Fuh | Bispecific anti-her antibodies |
WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
MY160556A (en) | 2010-02-18 | 2017-03-15 | Genentech Inc | Neuregulin antagonists and use thereof in treating cancer |
US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
EP2542589A4 (de) * | 2010-03-04 | 2013-08-07 | Symphogen As | Antikörper und zusammensetzungen gegen her2 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
NZ604007A (en) | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
JP6266343B2 (ja) | 2010-07-16 | 2018-01-24 | アディマブ, エルエルシー | 抗体ライブラリー |
WO2012047427A2 (en) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
EP2643353A1 (de) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispezifische moleküle |
EP2648738A2 (de) | 2010-12-06 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Dosierung und verabreichung zur verhinderung von kardiotoxizität bei der behandlung mit auf erbb2 gerichteten immunoliposomen mit chemotherapeutischen anthracyclinen |
SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
JP6054308B2 (ja) | 2011-02-15 | 2016-12-27 | メリマック ファーマシューティカルズ, インコーポレイテッドMerrimack Pharmaceuticals, Inc. | 核酸を細胞へ送達する組成物及び方法 |
CA2832387A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecifc antibodies against her2 |
US20140170149A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
BR112014003431A2 (pt) | 2011-08-17 | 2017-06-13 | Genentech Inc | anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor |
WO2013043864A1 (en) * | 2011-09-23 | 2013-03-28 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to endothelial targeting |
WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
CN104271761B (zh) | 2011-11-30 | 2017-03-15 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
EP2788500A1 (de) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identifizierung von non-respondern auf her2-inhibitoren |
JP2015514710A (ja) | 2012-03-27 | 2015-05-21 | ジェネンテック, インコーポレイテッド | Her3阻害剤に関する診断及び治療 |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
WO2013192294A1 (en) * | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
AU2013355337B2 (en) | 2012-12-03 | 2018-07-12 | Merrimack Pharmaceuticals, Inc. | Combination therapy for treating HER2-positive cancers |
WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
JP2017512765A (ja) | 2014-04-11 | 2017-05-25 | メディミューン,エルエルシー | 二重特異性her2抗体 |
TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
US20160045596A1 (en) | 2014-08-05 | 2016-02-18 | Merrimack Pharmaceuticals, Inc. | Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies |
US10632180B2 (en) | 2015-02-06 | 2020-04-28 | The Regents Of The University Of California | Methods and compositions for improved cognition |
EP3514181A1 (de) * | 2015-02-24 | 2019-07-24 | Academia Sinica | Phagenangezeigte einkettige variable fragment-bibliothek und daraus ausgewählte antikörper |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
EP3337478B1 (de) | 2015-08-21 | 2020-08-12 | Ipsen Biopharm Ltd. | Arzneimittelkombination enthaltend liposomales irinotecan, oxaliplatin, 5-fluorouracil und leucovorin zur behandlung von metastasierendem pankreaskrebs |
BR112018006922B1 (pt) | 2015-10-16 | 2023-11-21 | Ipsen Biopharm Ltd | Composições de irinotecano lipossômico estabilizado para armazenamento |
WO2017096361A1 (en) | 2015-12-04 | 2017-06-08 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
AU2016370376B2 (en) | 2015-12-14 | 2023-12-14 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
WO2018083470A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
EP3585431A4 (de) | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | Bispezifische, zur bindung von cd137- und tumorantigenen fähige bindungsmoleküle und verwendungen davon |
CA3085432A1 (en) | 2017-12-12 | 2019-06-20 | Macrogenics Inc. | Bispecific cd16-binding molecules and their use in the treatment of disease |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
EP3920887A4 (de) | 2019-02-04 | 2022-10-19 | The Regents of the University of California | Übungsinduzierte durchblutungsfaktoren zur verbesserung der kognitiven, neurologischen und regenerativen dysfunktion während der alterung |
CA3202218A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169774A (en) | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
US4996490A (en) * | 1986-11-18 | 1991-02-26 | Atlantic Richfield Company | Microwave apparatus and method for measuring fluid mixtures |
US5242824A (en) | 1988-12-22 | 1993-09-07 | Oncogen | Monoclonal antibody to human carcinomas |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
IL99553A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
AU685753B2 (en) | 1992-09-04 | 1998-01-29 | Scripps Research Institute, The | Phagemids coexpressing a surface receptor and a surface heterologous protein |
JPH08505524A (ja) | 1992-11-10 | 1996-06-18 | イグジス, インコーポレイティッド | 溶液中で拘束された二次コンホメーションを有する可溶性ペプチド、およびその製造方法 |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
WO1994026787A1 (en) | 1993-05-07 | 1994-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for generating cell type specific phage antibody libraries |
US5631158A (en) | 1993-10-25 | 1997-05-20 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from non-native DNA |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5736388A (en) | 1994-12-30 | 1998-04-07 | Chada; Sunil | Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells |
DE69638269D1 (de) | 1995-06-14 | 2010-11-18 | Univ California | Hochaffine humane antikörper gegen tumorantigene |
SE9503151D0 (sv) | 1995-09-13 | 1995-09-13 | Bioinvent Internatioal Ab | Combined ligand and receptor display |
CA2251738A1 (en) | 1996-04-16 | 1997-10-23 | Immusol Incorporated | Targeted viral vectors |
GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
WO1998005344A1 (en) | 1996-08-05 | 1998-02-12 | Brigham And Women's Hospital, Inc. | Bacteriophage-mediated gene therapy |
US6054312A (en) | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
AU6842701A (en) * | 2000-06-16 | 2002-01-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
-
1999
- 1999-02-12 US US09/250,056 patent/US7244826B1/en not_active Expired - Fee Related
- 1999-04-23 AT AT99919786T patent/ATE412432T1/de not_active IP Right Cessation
- 1999-04-23 EP EP99919786A patent/EP1071460B1/de not_active Expired - Lifetime
- 1999-04-23 JP JP2000545565A patent/JP2002524024A/ja active Pending
- 1999-04-23 AU AU37429/99A patent/AU769304B2/en not_active Revoked
- 1999-04-23 CA CA2326377A patent/CA2326377C/en not_active Expired - Fee Related
- 1999-04-23 ES ES99919786T patent/ES2316186T3/es not_active Expired - Lifetime
- 1999-04-23 DE DE69939820T patent/DE69939820D1/de not_active Expired - Lifetime
- 1999-04-23 WO PCT/US1999/007395 patent/WO1999055367A1/en active IP Right Grant
-
2007
- 2007-06-01 US US11/809,773 patent/US7892554B2/en not_active Expired - Fee Related
-
2010
- 2010-12-16 US US12/928,792 patent/US8173424B2/en not_active Expired - Fee Related
-
2012
- 2012-04-06 US US13/441,651 patent/US8974792B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 US US14/627,773 patent/US9388244B2/en not_active Expired - Fee Related
-
2016
- 2016-06-09 US US15/177,999 patent/US20160279262A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7892554B2 (en) | 2011-02-22 |
ATE412432T1 (de) | 2008-11-15 |
EP1071460A1 (de) | 2001-01-31 |
EP1071460A4 (de) | 2004-09-08 |
AU769304B2 (en) | 2004-01-22 |
WO1999055367A1 (en) | 1999-11-04 |
ES2316186T3 (es) | 2009-04-01 |
US20110218333A1 (en) | 2011-09-08 |
US8173424B2 (en) | 2012-05-08 |
US20150239976A1 (en) | 2015-08-27 |
US7244826B1 (en) | 2007-07-17 |
US20130337039A1 (en) | 2013-12-19 |
WO1999055367A9 (en) | 2000-03-02 |
US8974792B2 (en) | 2015-03-10 |
JP2002524024A (ja) | 2002-08-06 |
CA2326377A1 (en) | 1999-11-04 |
US20160279262A1 (en) | 2016-09-29 |
US9388244B2 (en) | 2016-07-12 |
EP1071460B1 (de) | 2008-10-29 |
US20080108135A1 (en) | 2008-05-08 |
AU3742999A (en) | 1999-11-16 |
CA2326377C (en) | 2016-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69939820D1 (de) | Internalisierende erbb2 antikörper | |
CY1119291T1 (el) | Πολυσθενη αντισωματα και χρησεις για αυτα | |
CY1122686T1 (el) | Ανταγωνιστικοι εκλεκτικοι παραγοντες συνδεσης της πρωτεϊνης συνδεσης οστεοπροτεγερινης | |
CY2019029I2 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
ATE544776T1 (de) | Chimäre dna-bindeproteine | |
YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
CY1112101T1 (el) | Νευροτροφικοι παραγοντες | |
ATE255906T1 (de) | Antikörper gegen cd40 | |
DE69429925T2 (de) | METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID | |
DE69638269D1 (de) | Hochaffine humane antikörper gegen tumorantigene | |
ATE386116T1 (de) | Bindungsdomänen des serrate-proteins | |
ATE255420T1 (de) | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung | |
GEP20105118B (en) | Anti-vegf antibodies | |
EP1106183A3 (de) | Antikörper gegen ErbB2 und deren therapeutische Verwendungen | |
DK1242452T3 (da) | Kimære natriuretiske peptider | |
RS53984B1 (en) | IP-10 ANTIBODIES AND THEIR USES | |
BR0011849A (pt) | Anticorpos enxertados lm609 melhorados | |
DE69838979D1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
BR0116686A (pt) | Anticorpos anti-cd28 silenciados e uso dos mesmos | |
IL139852A0 (en) | Monoclonal antibodies directed against the g3bp protein, and uses | |
ATE285474T1 (de) | Haemophilus adhäsionsproteinen | |
WO2001066752A3 (en) | Reproduction-specific genes | |
TR200003695T2 (tr) | Anjiyostatin bağlayıcı protein. | |
DK1208213T3 (da) | Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner | |
WO2002077648A3 (en) | Pathogenic and commensal vaccine antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |